Cost-effectiveness Analysis of Three Drugs in the Treatment of Chronic Hepatitis B
- VernacularTitle:3种药物治疗慢性乙型肝炎的成本-效果分析
- Author:
Li LI
;
Yan'An ZHOU
;
- Publication Type:Journal Article
- Keywords:
Lamivudine;
Adefovir dipivoxil;
Entecavir;
Chronic hepatitis B;
Cost-effectiveness analysis
- From:
Chinese Journal of Pharmacoepidemiology
2007;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the cost-effectiveness ratio among lamivudin(LMV),adefovir dipivoxil(AFD) and entecavir(ETC)in the treatment of chronic hepatitis B to find the best scheme.Method:1026 patients with chronic hepatitis B from 9 reports were given LMV(359 patients),SFD(345 patients)and ETC(322 patients)for 48 weeks.Then a cost-effectiveness analysis was carried out.Result:The cost for LMV was 5 231.52 yuan,the cost for AFD was 5006.4 yuan,and the cost for ETC was 12 559.68 yuan.The therapeutic effects were 42.90,51.59 and 76.09,respectively.The cost-effectiveness analyses of LMV,AFD and ETC were 121.95,97.04 and 165.06,respectively.Conclusion:AFD AFD is the best scheme in the treatment of chronic hepatitis B.
